Belite Bio (BLTE) EPS (Weighted Average and Diluted) (2022 - 2026)
Belite Bio (BLTE) recorded quarterly EPS (Weighted Average and Diluted) of $0.68 in Q1 2026, down 2.86% quarter-over-quarter from $0.7 in Q4 2025, and up 251.11% on a YoY basis from $0.19 in Q1 2025.
Belite Bio (BLTE) EPS (Weighted Average and Diluted) (2022 - 2026) Analysis & Trends
Belite Bio's EPS (Weighted Average and Diluted) history runs 5 years deep, the most recent figure standing at $0.68 for Q1 2026.
- In Q1 2026, EPS (Weighted Average and Diluted) rose 251.11% year-over-year to $0.68; the TTM figure through Mar 2026 stood at $0.23 (up 227.78% YoY), while the FY2025 annual figure was -$2.31, down 95.76% from the prior year.
- EPS (Weighted Average and Diluted) was $0.68 for Q1 2026 at Belite Bio, down from $0.7 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.7 in Q4 2025 to a low of -$0.65 in Q3 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.06 across 5 years, with a median of -$0.19 in 2022.
- Biggest YoY gain for EPS (Weighted Average and Diluted) was 318.75% in 2025; the steepest drop was 332.14% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.27 in 2022, then decreased by 7.41% to $0.25 in 2023, then slumped by 228.0% to -$0.32 in 2024, then surged by 318.75% to $0.7 in 2025, then retreated by 2.86% to $0.68 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $0.68 (Q1 2026), $0.7 (Q4 2025), and -$0.65 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | 6.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.68 |
| Dec 31, 2025 | 0.70 |
| Sep 30, 2025 | -0.65 |
| Jun 30, 2025 | -0.50 |
| Mar 31, 2025 | -0.45 |
| Dec 31, 2024 | -0.32 |
| Sep 30, 2024 | 0.28 |
| Jun 30, 2024 | 0.31 |
| Mar 31, 2024 | -0.27 |
| Dec 31, 2023 | 0.25 |
| Sep 30, 2023 | -0.40 |
| Jun 30, 2023 | -0.26 |
| Mar 31, 2023 | -0.33 |
| Dec 31, 2022 | 0.27 |
| Sep 30, 2022 | -0.10 |
| Jun 30, 2022 | -0.12 |